Nasdaq-listed 111, a Chinese healthcare platform, has entered into a strategic cooperation agreement with Jiangsu-based drug R&D firm Suzhou Zelgen Biopharmaceuticals Co. to build a virtual platform for liver cancer patients.
WHAT IT DOES
111 operates an internet hospital offering virtual health consultations, an electronic prescription service, and a patient management service. It also runs...
